Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Roth Capital decreased their Q1 2025 earnings estimates for shares of Curaleaf in a report issued on Thursday, May 1st. Roth Capital analyst W. Kirk now forecasts that the company will earn ($0.07) per share for the quarter, down from their prior estimate of ($0.06). The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Roth Capital also issued estimates for Curaleaf's FY2025 earnings at ($0.25) EPS and FY2026 earnings at ($0.21) EPS.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). Curaleaf had a negative net margin of 14.82% and a negative return on equity of 13.67%.
Curaleaf Trading Up 4.7 %
Shares of OTCMKTS:CURLF traded up $0.04 during midday trading on Monday, reaching $0.89. The company had a trading volume of 501,036 shares, compared to its average volume of 701,205. The firm has a market cap of $591.82 million, a price-to-earnings ratio of -3.08 and a beta of 0.83. The company has a fifty day simple moving average of $0.91 and a two-hundred day simple moving average of $1.49. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.51 and a current ratio of 1.11. Curaleaf has a 1-year low of $0.68 and a 1-year high of $6.01.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
See Also
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
